Abstract
Darbepoetin alfa (DA) is a standard treatment for anemia in lower-risk MDS. However, to date there has been no comparative study to investigate the initial dosage. We, thus, conducted a randomized controlled trial to elucidate the optimal initial dosage of DA. International Prognostic Scoring System low or intermediate-1 risk MDS patients with hemoglobin levels ≤9.0 g/dL, serum erythropoietin levels ≤500 mIU/mL, and red blood cell transfusion dependency were enrolled. Patients were randomized to receive DA either at 60, 120, or 240 μg/week for 16 weeks followed by continuous administration with dose adjustment up to 48 weeks. Of 17, 18, and 15 patients in the 60, 120, and 240 μg DA groups included in the efficacy analysis, 64.7, 44.4, and 66.7 %, respectively, achieved the primary endpoint (major or minor erythroid response), while 17.6, 16.7, and 33.3 % achieved major erythroid responses in the initial 16-week period. No clinically significant safety concerns were identified. DA reduced the transfusion requirements effectively and safely in transfusion-dependent, lower-risk MDS patients. Given the highest achievement rate of the major erythroid response in the 240 μg group and the absence of dose-dependent adverse events, 240 ...Continue Reading
References
Jan 1, 1991·Leukemia Research·C AulW Schneider
Jan 1, 1995·British Journal of Haematology·E Hellström-Lindberg
Dec 31, 1997·British Journal of Haematology·E Hellström-LindbergP Greenberg
Jan 14, 1999·British Journal of Haematology·P R FerriniE Balleari
Mar 22, 2003·British Journal of Haematology·Eva Hellström-LindbergUNKNOWN Scandinavian MDS Group
Oct 25, 2003·Lancet·Michael HenkeHermann Frommhold
Apr 1, 2004·Blood·Nicole CasadevallPierre Fenaux
Jan 11, 2005·British Journal of Haematology·Pellegrino MustoAngelo Michele Carella
Aug 10, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Brian Leyland-JonesEls Vercammen
Sep 17, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R StasiS Amadori
May 10, 2006·British Journal of Haematology·L MannoneUNKNOWN Groupe Francais des Myelodysplasies
Nov 23, 2006·Cancer·Pilar GiraldoUNKNOWN Aranesp in Myelodysplastic Syndromes (ARM) Study Group
Mar 30, 2007·British Journal of Haematology·Ali-Reza GolshayanMikkael A Sekeres
Oct 18, 2007·Blood·Sophie ParkUNKNOWN GFM group (Groupe Francophone des Myélodysplasies)
Oct 27, 2007·The Oncologist·Susan D RossGayatri Ranganathan
Jan 30, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert E SmithJohn A Glaspy
Mar 21, 2008·Annals of Hematology·Victor MoyoSuneel Mundle
Jun 11, 2008·British Journal of Haematology·Janice GabriloveLyndah Dreiling
Jun 19, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Martin JäderstenEva Hellström-Lindberg
Nov 14, 2008·American Journal of Hematology·Jason GotlibPeter L Greenberg
Jul 1, 2009·Blood·Peter L GreenbergJacob M Rowe
Mar 6, 2010·Expert Opinion on Biological Therapy·C Kelaidi, P Fenaux
Apr 7, 2010·Leukemia & Lymphoma·Esther N OlivaRoberto Latagliata
Jun 29, 2010·Leukemia Research·Sophie ParkFrançois Dreyfus
Mar 9, 2011·Current Medical Research and Opinion·A VillegasJ A Gasquet
Jun 29, 2012·Blood·Peter L GreenbergDetlef Haase
Sep 28, 2013·Blood·Valeria SantiniSophie Park
Citations
May 24, 2016·British Journal of Haematology·Sophie ParkHairong Xu
Jun 20, 2017·Leukemia·U PlatzbeckerJ Franklin
Jul 15, 2018·Cancer Science·Yasuyoshi MoritaMitsuhiro Matsuda
Oct 28, 2019·Annals of Hematology·Sophie ParkUwe Platzbecker
Dec 15, 2018·British Journal of Haematology·Sophie ParkPierre Fenaux